Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.00
Bid: 220.00
Ask: 222.50
Change: 1.00 (0.45%)
Spread: 2.50 (1.136%)
Open: 220.50
High: 223.50
Low: 218.00
Prev. Close: 221.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Puretech Health proposes $100m capital return

Tue, 19th Mar 2024 09:46

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

PureTech said on Tuesday that the proposed capital return represented approximately 14% of its market capitalisation based on Monday's closing price and noted that it follows a previous announcement that it will receive approximately $293.0m in gross proceeds from its remaining stake in Karuna.

The AIM-listed group said the offer will be launched after the publication of its full-year results in April, subject to market conditions, and will require shareholder approval.

PureTech added that if the full $100.0m was not returned, then it intends to return any remainder following the completion of the offer, by way of a special dividend.

Chief executive Daphne Zohar said: "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14.0bn is a testament to our execution on both fronts. We directed $18.5m to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1bn in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years.

"We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50.0m share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

As of 1055 GMT, PureTech shares were up 8.58% at 221.50p.

Reporting by Iain Gilbert at Sharecast.com

More News
9 Dec 2019 12:32

PureTech Health Investee Gelesis Gets USD85 Million For Plenity Launch

PureTech Health Investee Gelesis Gets USD85 Million For Plenity Launch

Read more
9 Dec 2019 09:37

PureTech affiliate Gelesis secures $84.6m in new capital

(Sharecast News) - Biotechnology commercialisation company PureTech Health noted on Monday that its affiliate Gelesis had secured $84.6m (£64.26m) in new capital.

Read more
5 Dec 2019 15:18

PureTech Affiliate Vedanta Gets USD6 Million Grant For VE707 Programme

PureTech Affiliate Vedanta Gets USD6 Million Grant For VE707 Programme

Read more
5 Dec 2019 08:14

PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant

(Sharecast News) - Clinical stage biotechnology company PureTech Health said on Thursday that its affiliate, Vedanta Biosciences, has been awarded a $5.8m grant for its 'VE707' programme, targeting multidrug resistant infections.

Read more
21 Nov 2019 10:49

PureTech Health Investee Karuna Prices USD250 Million Public Offering

PureTech Health Investee Karuna Prices USD250 Million Public Offering

Read more
20 Nov 2019 13:27

Wednesday broker round-up

(Sharecast News) - Burford Capital: Berenberg downgrades to hold with a target price of 810p.

Read more
19 Nov 2019 17:03

LONDON MARKET CLOSE: Pound Lower With Johnson And Corbyn To Square Off

LONDON MARKET CLOSE: Pound Lower With Johnson And Corbyn To Square Off

Read more
19 Nov 2019 12:20

PureTech Health surges on positive Karuna Therapeutics drug trial

(Sharecast News) - PureTech Health surged on Tuesday after US biopharmaceutical company Karuna Therapeutics - in which it owns a 32% stake - said a day earlier that a phase 2 trial of its schizophrenia treatment met its primary endpoint.

Read more
18 Nov 2019 16:58

LONDON MARKET CLOSE: Stocks End Higher Despite US-China Trade Doubts

LONDON MARKET CLOSE: Stocks End Higher Despite US-China Trade Doubts

Read more
18 Nov 2019 11:57

PureTech Health's Unit Reports Positive KarXT Clinical Trial Results

PureTech Health's Unit Reports Positive KarXT Clinical Trial Results

Read more
18 Nov 2019 10:22

UK WINNERS & LOSERS SUMMARY: Consort Medical Rises On Takeover Offer

UK WINNERS & LOSERS SUMMARY: Consort Medical Rises On Takeover Offer

Read more
15 Nov 2019 16:54

LONDON MARKET CLOSE: FTSE 100 Shrugs Off BT Decline Amid Trade Hopes

LONDON MARKET CLOSE: FTSE 100 Shrugs Off BT Decline Amid Trade Hopes

Read more
15 Nov 2019 13:49

PureTech Shares Down As Investee Halts Work After Poor Results

PureTech Shares Down As Investee Halts Work After Poor Results

Read more
5 Nov 2019 14:54

PureTech Reports New Data From Its Immuno-Oncology Programmes

PureTech Reports New Data From Its Immuno-Oncology Programmes

Read more
24 Oct 2019 08:09

PureTech affiliate Sonde Health names David Liu as CEO

(Sharecast News) - Clinical stage biotechnology company PureTech Health announced on Thursday that its affiliate Sonde Health had appointed David Liu as chief executive officer and a member of its board of directors.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.